Encellin Partners with Breakthrough T1D to Advance Immune-Protected Cell Therapy for Type 1 Diabetes

SAN FRANCISCO & NEW YORK & MONTREAL — Encellin, Inc., a clinical-stage biotechnology company developing Encapsulated Cell Replacement Therapy (ENCRT), today announced a partnership with Breakthrough T1D, the leading global Type 1 Diabetes (T1D) research and advocacy organization, and an award through its Industry Discovery and Development Partnership (IDDP) program to support the advancement of […]